洁特生物(688026) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥74,281,810.80, representing a decrease of 60.98% compared to the same period last year[2] - The net profit attributable to shareholders was -¥8,797,295.17, a decline of 121.45% year-over-year[2] - Total revenue for Q1 2023 was CNY 74,281,810.80, a decrease of 61.0% compared to CNY 190,362,813.69 in Q1 2022[16] - The net loss for Q1 2023 was CNY 8,741,237.41, compared to a net profit of CNY 41,015,898.04 in Q1 2022, indicating a significant decline in profitability[17] - Operating profit for Q1 2023 was CNY -8,164,495.07, a decrease from CNY 47,660,359.74 in the same period last year[17] Cash Flow - The net cash flow from operating activities increased by 57.71% to ¥32,825,677.22[2] - In Q1 2023, the cash inflow from operating activities was $113,846,781.35, a decrease of 46.4% compared to $212,236,160.54 in Q1 2022[21] - The net cash outflow from operating activities was $81,021,104.13, down from $191,422,525.03 in the same period last year, resulting in a net cash flow from operating activities of $32,825,677.22, an increase of 57.5% year-over-year[22] - The cash inflow from investment activities totaled $70,357,044.95, while cash outflow was $114,910,710.57, leading to a net cash flow from investment activities of -$44,553,665.62, an improvement from -$77,178,782.19 in Q1 2022[22] - The cash flow from financing activities resulted in a net outflow of $1,763,127.43, compared to a net outflow of $2,469,321.10 in the previous year, indicating a 28.5% reduction in cash outflow[22] Assets and Liabilities - The total assets at the end of Q1 2023 were ¥1,582,523,905.09, a decrease of 1.42% from the end of the previous year[3] - The company's total assets as of Q1 2023 were CNY 1,582,523,905.09, slightly down from CNY 1,605,340,593.15 in Q1 2022[15] - Total liabilities decreased to CNY 451,130,703.31 in Q1 2023 from CNY 465,208,287.98 in Q1 2022, a reduction of 3.0%[15] - The total current assets amounted to ¥808.87 million, down from ¥848.62 million at the end of 2022[13] - The total non-current assets amounted to CNY 773,656,320.74 in Q1 2023, compared to CNY 756,721,497.98 in Q1 2022, showing an increase of 2.2%[15] Shareholder Information - The total number of common shareholders at the end of the reporting period was 7,029[10] - The largest shareholder, Yuan Jianhua, holds 30.98% of the shares, totaling 43,484,584 shares[10] Research and Development - Research and development expenses totaled ¥6,854,150.51, accounting for 9.23% of operating revenue, which is an increase of 4.14 percentage points[2] - Research and development expenses for Q1 2023 were CNY 6,854,150.51, down from CNY 9,684,707.76 in Q1 2022, a decrease of 29.0%[17] Market and Product Development - The company has no significant new product launches or technological developments reported in the current quarter[12] - There are no major market expansions or acquisitions mentioned in the latest report[12] - The company has not provided specific future guidance or performance outlook in the current report[12] Revenue Breakdown - Revenue from consumables was ¥72,990,100, a year-over-year decline of 61.16%[6] - Revenue from international customers decreased by 67.19% to ¥42,650,000, with specific declines in pipette tips and suction heads of 80.22% and 74.20%, respectively[7] - The comprehensive gross margin for consumable products dropped to 23.41%, down from 38.57% in the same period last year[8] Cash and Equivalents - The company's cash and cash equivalents as of March 31, 2023, were approximately ¥579.85 million, a decrease from ¥598.88 million at the end of 2022[13] - The total cash and cash equivalents at the end of Q1 2023 were $295,490,898.71, compared to $202,944,762.76 at the end of Q1 2022, reflecting a year-over-year increase of 45.5%[22] Other Financial Metrics - The issuance of convertible bonds in June 2022 resulted in an additional interest expense of ¥6,060,000 for the current period[8] - The company reported a basic and diluted earnings per share of CNY -0.06 for Q1 2023, compared to CNY 0.29 in Q1 2022[18] - Accounts receivable decreased to ¥85.85 million from ¥104.95 million year-over-year[13] - Inventory increased slightly to ¥126.04 million from ¥124.81 million at the end of 2022[13] - The company has not adopted new accounting standards for the current year, maintaining consistency in financial reporting[23]